Overview

Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the renal hemodynamic effect of RLX030 infusion in subjects with chronic heart failure. In addition safety and effects on renal function and biomarkers will be assessed.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals